The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile
Abstract
Despite the increasing clinical use of transdermal buprenorphine, questions have persisted about the possibility of a ceiling effect for analgesia, its combination with other μ-opioid agonists, and the reversibility of side effects. In October 2008, a consensus group of experts met to review recent research into the pharmacology and clinical use of buprenorphine. The objective was to achieve consensus on the conclusions to be drawn from this work. It was agreed that buprenorphine clearly behaves as a full μ-opioid agonist for analgesia in clinical practice, with no ceiling effect, but that there is a ceiling effect for respiratory depression, reducing the likelihood of this potentially fatal adverse event. This is entirely consistent with receptor theory. In addition, the effects of buprenorphine can be completely reversed by naloxone. No problems are encountered when switching to and from buprenorphine and other opioids, or in combining them. Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain. Other beneficial properties are the compound's favorable safety profile, particularly in elderly patients and those with renal impairment, and its lack of effect on sex hormones and the immune system. The expert group agreed that these properties, as well as proven efficacy in severe pain and favorable tolerability, mean that buprenorphine can be considered a safe and effective option for treating chronic cancer and noncancer pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126 · cited 1×
“Opioid analgesics and tramadol are also recommended for the treatment of neuropathic pain by international guidelines, generally as second-line treatments that can be considered for first-line use in particular clinical circumstances.(103) A body of evidence from preclinical and experimental human studies supports the…”
BackgroundLong-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine
Célèrier, E., Rivat, C., Jun, Y., Laulin, J.-P., Larcher, A., Reynier, P., & Simonnet, G. (2000) · Anesthesiology · doi:10.1097/00000542-200002000-00029 · Cited by 584 · cited 2×
“Moreover, experimental studies and clinical observations suggest that pure m-opioid receptor agonists may contribute to the induction of hyperalgesia.(24) Therefore, different mechanisms have been proposed for opioid-induced analgesia and antihyperalgesia, possibly with different pharmacodynamics.”
Background
Cited by
An overview of treatment approaches for chronic pain management
Hylands-White, N., Duarte, R. V., & Raphael, J. H. (2017) · Rheumatology International · doi:10.1007/s00296-016-3481-8 · Cited by 387
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
The clinical analgesic efficacy of buprenorphine
Raffa, R. B., Haidery, M., Huang, H.-M., Kalladeen, K., Lockstein, D. E., Ono, H., Shope, M. J., Sowunmi, O. A., Tran, J. K., & Pergolizzi, J. V. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12196 · Cited by 105
Self-citationBuprenorphine—Clinically useful but often misunderstood
Butler, S. (2013) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2013.05.004 · Cited by 47
Metadata
- Authors
- Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Likar, R., Mercadante, S., Morlion, B., Raffa, R. B., Sabatowski, R., Sacerdote, P., Torres, L. M., & Weinbroum, A. A.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2010-08-30
- Volume
- 10
- Issue
- 5
- Pages
- 428-450
- ISSN
- 1530-7085 (ISSN-L)
- OpenAlex
- W1951897616
- Cited by
- 284
- References
- 2
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. https://app.cochat.ai/papers/10.1111/j.1533-2500.2010.00378.x
- The paper
- Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Likar, R., Mercadante, S., Morlion, B., Raffa, R. B., Sabatowski, R., Sacerdote, P., Torres, L. M., & Weinbroum, A. A. (2010). Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. Pain Practice. https://doi.org/10.1111/j.1533-2500.2010.00378.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
